Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
实体瘤患者接种SARS-CoV-2疫苗后可获得足够的免疫原性,且严重不良事件发生率较低。
期刊:Future Oncology
影响因子:2.6
doi:10.2217/fon-2022-0148
Janzic, Urska; Bidovec-Stojkovic, Urska; Mohorcic, Katja; Mrak, Loredana; Dovnik, Nina Fokter; Ivanovic, Marija; Ravnik, Maja; Caks, Marina; Skof, Erik; Debeljak, Jerneja; Korosec, Peter; Rijavec, Matija